FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 90 filers reported holding FATE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195 | -92.4% | 91,864 | -82.9% | 0.01% | -91.9% |
| Q2 2023 | $2,555 | +17.8% | 536,831 | +41.1% | 0.11% | +8.8% |
| Q1 2023 | $2,169 | -99.7% | 380,537 | +1681.9% | 0.10% | +88.9% |
| Q1 2022 | $828,000 | +55.3% | 21,356 | +134.4% | 0.05% | -19.4% |
| Q4 2021 | $533,000 | +13.6% | 9,111 | +15.0% | 0.07% | +8.1% |
| Q3 2021 | $469,000 | +172.7% | 7,921 | -54.9% | 0.06% | +87.9% |
| Q1 2018 | $172,000 | -38.6% | 17,580 | -75.1% | 0.03% | -48.4% |
| Q3 2017 | $280,000 | -15.4% | 70,677 | -30.8% | 0.06% | -31.2% |
| Q2 2017 | $331,000 | – | 102,169 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |